HomeCompareNGM vs SBUX

NGM vs SBUX: Dividend Comparison 2026

NGM yields 129.87% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NGM wins by $12.15M in total portfolio value
10 years
NGM
NGM
● Live price
129.87%
Share price
$1.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.32M
Annual income
$4,899,840.26
Full NGM calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — NGM vs SBUX

📍 NGM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNGMSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NGM + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NGM pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NGM
Annual income on $10K today (after 15% tax)
$11,038.96/yr
After 10yr DRIP, annual income (after tax)
$4,164,864.22/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, NGM beats the other by $4,104,398.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NGM + SBUX for your $10,000?

NGM: 50%SBUX: 50%
100% SBUX50/50100% NGM
Portfolio after 10yr
$6.24M
Annual income
$2,485,488.36/yr
Blended yield
39.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

NGM
Analyst Ratings
10
Buy
5
Hold
Consensus: Buy
Price Target
$16.50
+971.4% upside vs current
Range: $4.00 — $29.00
Altman Z
-4.1
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NGM buys
0
SBUX buys
0
No recent congressional trades found for NGM or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNGMSBUX
Forward yield129.87%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$12.32M$167.0K
Annual income after 10y$4,899,840.26$71,136.45
Total dividends collected$11.28M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$16.50$104.00

Year-by-year: NGM vs SBUX ($10,000, DRIP)

YearNGM PortfolioNGM Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$23,687$12,987.01$11,121$420.68+$12.6KNGM
2$54,095$28,749.86$12,548$648.40+$41.5KNGM
3$119,243$61,361.87$14,440$1,013.98+$104.8KNGM
4$254,004$126,413.25$17,068$1,617.30+$236.9KNGM
5$523,444$251,660.09$20,912$2,649.52+$502.5KNGM
6$1,044,772$484,686.28$26,875$4,499.29+$1.02MNGM
7$2,022,029$904,123.86$36,771$8,014.12+$1.99MNGM
8$3,798,920$1,635,348.40$54,542$15,197.11+$3.74MNGM
9$6,936,280$2,871,436.26$89,602$31,242.49+$6.85MNGM
10$12,321,660$4,899,840.26$167,011$71,136.45+$12.15MNGM

NGM vs SBUX: Complete Analysis 2026

NGMStock

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Full NGM Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this NGM vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NGM vs SCHDNGM vs JEPINGM vs ONGM vs KONGM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.